Indinavir sulfate renal toxicity in a pediatric hemophiliac with HIV infection

• Published in: The Annals of pharmacotherapy Vol. 31; no. 10; p. 1146
• Main Authors: Ascher, D P, Lucy, M D
• Format: Journal Article
• Language: English
• Published: United States 01-10-1997
• Subjects: Adolescent; Factor VIII - adverse effects; Hemophilia A - complications; Hemophilia A - therapy; HIV Infections - complications; HIV Infections - drug therapy; HIV Infections - etiology; HIV Protease Inhibitors - adverse effects; Humans; Indinavir - adverse effects; Male; Nephritis, Interstitial - chemically induced
• ISSN: 1060-0280
• DOI: 10.1177/106002809703101005

To report a case of renal toxicity associated with administration of indinavir sulfate in a pediatric hemophiliac with HIV infection.
A 16-year-old white hemophiliac boy with HIV infection secondary to tainted coagulation factor VIII was treated with indinavir sulfate. The patient developed gross hematuria, proteinuria, pyuria, abdominal pain, increased bilirubin, an elevated serum creatinine (SCr) of 1.2 mg/dL (baseline 0.9-1.0), and symptoms of renal colic within 1 month of starting indinavir sulfate therapy. Approximately 2 months later the patient developed a low-grade fever with a further increase in SCr. He was prescribed a 10-day course of cefpodoxime proxetil for a possible urinary tract infection. One week later, the patient developed fever, chills, nausea, vomiting, decreased appetite, sterile pyuria, nasal congestion, and an elevated SCr of 1.3-1.7 mg/dL. Indinavir sulfate and cefpodoxime proxetil were discontinued and the patient was suspected of having tubulointerstitial nephritis secondary to indinavir sulfate. The patient's nephritis resolved and the SCr decreased to 1.1 mg/dL within 1 month of discontinuing indinavir sulfate.
This case demonstrates the potential for renal toxicity with the use of indinavir sulfate in HIV-infected hemophiliacs.